ERBB2 and breast carcinoma: HER-2 overexpression is gaining acceptance as an indicator that defines breast cancer patients who should preferentially receive anthracycline-based or CMF adjuvant or therapeutic treatment (Paik et al, 1998; Thor et al, 1998; Hamilton and Piccart, 2000; Andrulis et al, 1998).